Skip to main content

. 1982 Feb;13(2):240–241. doi: 10.1111/j.1365-2125.1982.tb01367.x

Verapamil bioavailability and dosage in liver disease.

B G Woodcock, N Rietbrock

PMCID: PMC1401981 PMID: 7059425

240

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Schomerus M., Spiegelhalder B., Stieren B., Eichelbaum M. Physiological disposition of verapamil in man. Cardiovasc Res. 1976 Sep;10(5):605–612. doi: 10.1093/cvr/10.5.605. [DOI] [PubMed] [Google Scholar]
Somogyi A., Albrecht M., Kliems G., Schäfer K., Eichelbaum M. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol. 1981 Jul;12(1):51–60. doi: 10.1111/j.1365-2125.1981.tb01854.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]
Woodcock B. G., Hopf R., Kaltenbach M. Verapamil and norverapamil plasma concentrations during long-term therapy in patients with hypertrophic obstructive cardiomyopathy. J Cardiovasc Pharmacol. 1980 Jan-Feb;2(1):17–23. doi: 10.1097/00005344-198001000-00003. [DOI] [PubMed] [Google Scholar]
Woodcock B. G., Rietbrock I., Vöhringer H. F., Rietbrock N. Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships. Clin Pharmacol Ther. 1981 Jan;29(1):27–34. doi: 10.1038/clpt.1981.5. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES